Considering the large number of mRNAs targeted by FMRP and the various dysregulated pathways, most of these clinical trials with a single drug were inconclusive, probably due to compensation mechanisms within a very complex scenario (mRNAs, pathways and/or FXS clinical phenotype) [63]. Here, FMR1 is linked to fragile X syndrome.